The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
Ho CY, McMurray JJV, Cirino AL, Colan SD, Day SM, Desai AS, Lipshultz SE, MacRae CA, Shi L, Solomon SD, Orav EJ, Braunwald E; VANISH trial investigators and executive committee.
Ho CY, et al. Among authors: orav ej.
Am Heart J. 2017 May;187:145-155. doi: 10.1016/j.ahj.2017.02.008. Epub 2017 Feb 16.
Am Heart J. 2017.
PMID: 28454798
Free PMC article.
Clinical Trial.